Get the Stockscreener App
38.32
2.22%
-0.87
After Hours:
38.47
0.15
+0.39%
Terns Pharmaceuticals Inc stock is traded at $38.32, with a volume of 2.28M.
It is down -2.22% in the last 24 hours and up +30.52% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$39.19
Open:
$39.91
24h Volume:
2.28M
Relative Volume:
0.61
Market Cap:
$4.17B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-29.03
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
-5.59%
1M Performance:
+30.52%
6M Performance:
+787.04%
1Y Performance:
+571.10%
1-Day Range:
$37.37
$39.97
1-Week Range:
$37.37
$41.26
52-Week Range:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
38.32 | 4.26B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
With 53% Institutional Ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Is a Favorite Amongst the Big Guns - 富途牛牛
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential - Insider Monkey
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
Terns Pharmaceuticals Earnings Notes - Trefis
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale - ts2.tech
Terns Pharmaceuticals stock soars after leukemia drug delivers big early responses in tough-to-treat patients - MSN
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Truist Securities maintains Terns Pharmaceuticals (TERN) buy recommendation - MSN
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 DataHas The Bull Case Changed? - Sahm
Jim Cramer highlights massive gains for Terns Pharmaceuticals shareholders - MSN
Terns Pharmaceuticals (TERN) Price Target Increased by 75.91% to 54.63 - Nasdaq
Will Terns Pharmaceuticals Inc. stock gain from government policies2025 Bull vs Bear & Weekly High Potential Alerts - moha.gov.vn
How Terns Pharmaceuticals Inc. stock performs in weak economyEarnings Performance Report & High Conviction Trade Alerts - Улправда
Is Terns Pharmaceuticals Inc. stock attractive for long term wealth buildingJobs Report & Target Return Focused Stock Picks - Улправда
Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders - Finviz
Terns Pharmaceuticals unveils promising phase 1 trial data - MSN
Insider Trends: How Terns Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - Улправда
Is Terns Pharmaceuticals Inc. stock a contrarian buy2025 Price Momentum & Free High Accuracy Swing Entry Alerts - Улправда
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next - ts2.tech
Jim Cramer Was Asked About These 11 Stocks - Insider Monkey
Operating cash flow per share of Terns Pharmaceuticals, Inc. – GETTEX:430 - TradingView — Track All Markets
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025) - ts2.tech
Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701 - simplywall.st
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid LeukemiaSlideshow (NASDAQ:TERN) 2025-12-15 - Seeking Alpha
Terns CEO Amy Burroughs talks cancer drug trial win - CNBC
Biotech ETF SBIO Hovers Near Peak on Rally - ETF Database
Terns Pharmaceuticals raises $747.5 million in upsized offering - Traders Union
Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial - Finviz
10 Stocks Delivering Explosive 18-190% Gains - Insider Monkey
Terns Pharmaceuticals (TERN) Price Target Increased by 65.68% to 26.75 - MSN
Why Terns Pharmaceuticals (TERN) Is Up 73.6% After Upsized Equity Raise On Strong TERN-701 Data - Sahm
Terns Pharma (TERN) Stock Analysis Report | Financials & Insights - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Terns Pharmaceutical prices stock at $40 per share - MSN
Citizens Maintains Terns Pharmaceuticals (TERN) Market Outperform Recommendation - MSN
Terns Pharmaceuticals raises $747.5 million in public offering - Investing.com
Terns Pharmaceuticals raises $747.5 million in public offering By Investing.com - Investing.com Australia
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):